헬릭스미스
Financials
Valuation Metrics
헬릭스미스's Market Cap is ₩1406B. At end of 2025 it was ₩2867B. Ranked #1061 of 2,421 in KR market (top 44%), #545 of 1,640 on KOSDAQ (top 33%), #122 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 140.58B KRW | KR#1,061/2,421 Sec#122/231 |
| Revenue | 2.42B KRW | KR#2,378/2,421 Sec#211/231 |
| Net Income | -1.63B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 143.20B KRW | KR#1,543/2,421 Sec#119/231 |
| Net Assets | 141.52B KRW | KR#1,174/2,421 Sec#87/231 |
| Employees | 44 | KR#2,099/2,421 Sec#192/231 |
| Value | ||
| P/B | 0.99x | KR#1,454/2,421 Sec#91/231 |
| P/S | 58.10x | KR#2,377/2,421 Sec#199/231 |
| FCF Yield | -5.06% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -1.15% | KR#1,632/2,421 Sec#113/231 |
| ROA | -1.14% | KR#1,691/2,421 Sec#119/231 |
| Op. Margin | -389.76% | KR#2,358/2,421 Sec#198/231 |
| Revenue Growth | -51.40% | KR#2,293/2,421 Sec#204/231 |
| Earnings Growth | -129.96% | KR#1,184/2,421 Sec#76/231 |
| Financial Health | ||
| Debt Ratio | 1.18% | KR#4/2,421 Sec#3/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -7.11B KRW | KR#1,598/2,421 Sec#133/231 |
| Cash | 31.83B KRW | KR#975/2,421 Sec#65/231 |
| Current Ratio | 56.69x | KR#5/2,421 Sec#2/231 |
| Performance | ||
| 1Y Return | -52.64% | KR#2,101/2,421 Sec#194/231 |
| 1M Return | -2.71% | KR#1,556/2,421 Sec#123/231 |
| From 52W High | -69.38% | KR#2,177/2,421 Sec#186/231 |
| 1Y MDD | -70.38% | KR#2,004/2,421 Sec#173/231 |
| Trading | ||
| Volume | 43,045 shares | KR#1,199/2,421 Sec#119/231 |
| Trading Value | 131.2M KRW | KR#1,439/2,421 Sec#146/231 |
| Foreign Own. | 4.01% | KR#1,048/2,421 Sec#93/231 |
| Per Share | ||
| EPS | -35 KRW | KR—/2,421 Sec—/231 |
| BPS | 3,070 KRW | KR#1,846/2,421 Sec#139/231 |
Company Info
Established in 1996, this R&D company was listed on KOSDAQ in 2005. It possesses global biotech-level resources and capabilities spanning from candidate substance discovery to preclinical trials, analysis, and production. The company provides diverse platform-based services, leveraging its experience with US FDA Orphan Drug, Fast Track, and RMAT designations. Building on its new material development expertise, it conducts B2B businesses for health functional foods and premium cosmetics. Helixmith is headquartered in Gangseo-gu, Seoul.